


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**

**“METHACHOLINE CHLORIDE POWDER FOR SOLUTION, FOR INHALATION”  
OBTAINED DRUG REGISTRATION CERTIFICATE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “Methacholine Chloride Powder for Solution, for Inhalation” (Tian Qing Su Xin (天晴速信)), a drug developed by the Group, has been granted drug registration certificate by the National Medical Products Administration of China. Tian Qing Su Xin was filed as a Chemicals Category 3 drug, and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs. The approved indication is: For the diagnosis of bronchial airway hyperresponsiveness in adults and children aged 5 and above without clinically apparent asthma, formulated as a solution for administration by aerosol inhalation. The brandname drug of its kind has not been launched in China, and the Methacholine Chloride Powder for Solution, for Inhalation, developed by the Group is currently the only provocative agent approved for bronchial provocation test in China.

Methacholine Chloride, a beta-methyl analog of acetylcholine, acts directly on acetylcholine receptors, causing contraction of bronchial smooth muscle. The clinical use of Methacholine Chloride Powder for Solution, for Inhalation to diagnose airway responsiveness can help assess asthma severity and guide adjustment of treatment regimens. Methacholine Chloride has been recommended by authoritative domestic and international guidelines for pulmonary function examination and diagnosis and treatment as one of the tools of bronchial provocation test.

Previously, Methacholine Chloride and histamine, which were used in provocation test in China, were neither approved as special reagents for pulmonary function testers nor approved as drugs, and the related products could not be legally used in clinical institutions. The approval for the launch of Tian Qing Su Xin can effectively address the urgent clinical need and help promote the progress of asthma prevention and control in China.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 28 March 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*